113P Translational analysis of acasunlimab in combination with pembrolizumab in CPI-treated metastatic NSCLC
Acasunlimab (DuoBody®-PD-L1x4-1BB) is a bispecific antibody immunotherapy designed to reinvigorate antitumor activity via conditional 4-1BB activation dependent on co-PD-L1 binding. Acasunlimab was evaluated in a Ph2 study (NCT05117242) in checkpoint inhibitor (CPI)- and chemotherapy (chemo)-treated PD-L1+ metastatic NSCLC as monotherapy (Arm A: 100 mg Q3W x2 cycles then 500 mg Q6W) or in combination (combo) with pembrolizumab (pembro) to maximize PD-1 blockade (Arm B: 100 mg + pembro 200 mg Q3W; Arm C: 100 mg + pembro 400 mg Q6W).
Authors
- Nathan Cheadle
- Yanhong Zhou (ORCID: https://orcid.org/0000-0003-2744-2100)
- Lisa R. Grimm
- M.R. Smith (ORCID: https://orcid.org/0000-0003-0482-7315)
- Nora Pencheva (ORCID: https://orcid.org/0009-0006-4689-1218)
- Luis G. Paz-Ares
- T.C. Wehler
- T.J. Ong
- J.G. Aerts
- P. Garrido Castro
- J. Blum
- G. Masters
- E. Felip
- B. Hubbard
- M.J. Chisamore
- S. Sridhar
- M. Jure-Kunkel
- K. Jansson
- B. Besse
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Genmab (United States) (US)
- Universitätsklinikum Gießen und Marburg (DE)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Erasmus MC (NL)
- Research Institute Hospital 12 de Octubre (ES)
- Genmab (Netherlands) (NL)
- Vall d'Hebron Hospital Universitari (ES)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106420
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00